vs
ASP Isotopes Inc.（ASPI）与null（EDIT）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是ASP Isotopes Inc.的1.5倍（$24.7M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs -19.2%），null自由现金流更多（$-36.4M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Editas Medicine是一家处于临床阶段的生物技术企业，总部位于马萨诸塞州剑桥市，在科罗拉多州博尔德市也设有研发场地，目前公司依托CRISPR基因编辑技术，开发针对罕见疾病的治疗方案。
ASPI vs EDIT — 直观对比
营收规模更大
EDIT
是对方的1.5倍
$16.7M
营收增速更快
ASPI
高出1314.8%
-19.2%
自由现金流更多
EDIT
多$11.0M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $24.7M |
| 净利润 | — | $-5.6M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -31.3% |
| 净利率 | — | -22.7% |
| 营收同比 | 1295.7% | -19.2% |
| 净利润同比 | -586.8% | 87.6% |
| 每股收益（稀释后） | — | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIEDIT
| Q4 25 | $16.7M | $24.7M | ||
| Q3 25 | $4.9M | $7.5M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $30.6M | ||
| Q3 24 | — | $61.0K | ||
| Q2 24 | — | $513.0K | ||
| Q1 24 | — | $1.1M |
净利润ASPIEDIT
| Q4 25 | — | $-5.6M | ||
| Q3 25 | $-12.9M | $-25.1M | ||
| Q2 25 | — | $-53.2M | ||
| Q1 25 | — | $-76.1M | ||
| Q4 24 | — | $-45.4M | ||
| Q3 24 | — | $-62.1M | ||
| Q2 24 | — | $-67.6M | ||
| Q1 24 | — | $-62.0M |
毛利率ASPIEDIT
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ASPIEDIT
| Q4 25 | — | -31.3% | ||
| Q3 25 | -306.1% | -325.4% | ||
| Q2 25 | — | -1440.6% | ||
| Q1 25 | — | -1635.1% | ||
| Q4 24 | — | -152.2% | ||
| Q3 24 | — | -107649.2% | ||
| Q2 24 | — | -14016.2% | ||
| Q1 24 | — | -5902.3% |
净利率ASPIEDIT
| Q4 25 | — | -22.7% | ||
| Q3 25 | -263.7% | -333.0% | ||
| Q2 25 | — | -1487.8% | ||
| Q1 25 | — | -1633.5% | ||
| Q4 24 | — | -148.3% | ||
| Q3 24 | — | -101870.5% | ||
| Q2 24 | — | -13178.8% | ||
| Q1 24 | — | -5458.1% |
每股收益（稀释后）ASPIEDIT
| Q4 25 | — | $0.03 | ||
| Q3 25 | $-0.15 | $-0.28 | ||
| Q2 25 | — | $-0.63 | ||
| Q1 25 | — | $-0.92 | ||
| Q4 24 | — | $-0.55 | ||
| Q3 24 | — | $-0.75 | ||
| Q2 24 | — | $-0.82 | ||
| Q1 24 | — | $-0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $146.6M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $27.3M |
| 总资产 | $498.0M | $186.5M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIEDIT
| Q4 25 | $333.3M | $146.6M | ||
| Q3 25 | $113.9M | $165.6M | ||
| Q2 25 | — | $178.5M | ||
| Q1 25 | — | $221.0M | ||
| Q4 24 | — | $269.9M | ||
| Q3 24 | — | $265.1M | ||
| Q2 24 | — | $279.1M | ||
| Q1 24 | — | $296.2M |
总债务ASPIEDIT
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $57.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPIEDIT
| Q4 25 | $204.2M | $27.3M | ||
| Q3 25 | $74.1M | $13.5M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $62.4M | ||
| Q4 24 | — | $134.3M | ||
| Q3 24 | — | $175.6M | ||
| Q2 24 | — | $232.0M | ||
| Q1 24 | — | $294.4M |
总资产ASPIEDIT
| Q4 25 | $498.0M | $186.5M | ||
| Q3 25 | $225.9M | $201.8M | ||
| Q2 25 | — | $210.6M | ||
| Q1 25 | — | $263.7M | ||
| Q4 24 | — | $341.6M | ||
| Q3 24 | — | $327.6M | ||
| Q2 24 | — | $384.8M | ||
| Q1 24 | — | $440.3M |
负债/权益比ASPIEDIT
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-36.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-36.4M |
| 自由现金流率自由现金流/营收 | -284.7% | -147.3% |
| 资本支出强度资本支出/营收 | 57.9% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIEDIT
| Q4 25 | $-37.8M | $-36.4M | ||
| Q3 25 | $-8.9M | $-30.8M | ||
| Q2 25 | — | $-50.2M | ||
| Q1 25 | — | $-47.8M | ||
| Q4 24 | — | $-50.8M | ||
| Q3 24 | — | $-52.6M | ||
| Q2 24 | — | $-57.1M | ||
| Q1 24 | — | $-49.9M |
自由现金流ASPIEDIT
| Q4 25 | $-47.4M | $-36.4M | ||
| Q3 25 | $-12.0M | $-31.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-47.9M | ||
| Q4 24 | — | $-51.3M | ||
| Q3 24 | — | $-55.5M | ||
| Q2 24 | — | $-60.6M | ||
| Q1 24 | — | $-51.7M |
自由现金流率ASPIEDIT
| Q4 25 | -284.7% | -147.3% | ||
| Q3 25 | -245.5% | -414.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1028.6% | ||
| Q4 24 | — | -167.6% | ||
| Q3 24 | — | -90998.4% | ||
| Q2 24 | — | -11804.3% | ||
| Q1 24 | — | -4558.9% |
资本支出强度ASPIEDIT
| Q4 25 | 57.9% | 0.2% | ||
| Q3 25 | 64.4% | 5.7% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 4788.5% | ||
| Q2 24 | — | 681.1% | ||
| Q1 24 | — | 164.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
